{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000297","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.128266+00:00","generated_at":"2026-06-06T22:20:10.184626+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules","bullets":["Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.","Revisions to stockholder nomination procedures to comply with universal proxy card rules (Rule 14a-19).","Limits stockholder nominee count to number of directors to be elected; clarifies timing for substitute nominations.","Requires soliciting stockholders to use a proxy card color other than white.","Technical and administrative changes also adopted."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000297","json":"https://secwatch.observer/filing/0001171843-24-000297.json","markdown":"https://secwatch.observer/filing/0001171843-24-000297.md","text":"https://secwatch.observer/filing/0001171843-24-000297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/0001171843-24-000297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/f8k_011824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:20:10.184626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4095a86855b65b493f320e407c1258bbca605f1","claim":"BIOCRYST PHARMACEUTICALS INC: Amended and Restated By-Laws effective January 16, 2024, including updates to align with Delaware law, revisions to stockholder meeting and nomination procedures, universal proxy rules, and technical changes (effective 2024-01-16).","evidence_excerpt":"On January 16, 2024, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company” or “BioCryst”) approved and adopted Amended and Restated By-Laws of the Company (as so amended and restated, the “By-Laws”), that became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/0001171843-24-000297-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}